Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study
PLOS ONE · 31.05.2024 · 19 (5) · e0304556
DOI: 10.1371/journal.pone.0304556 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, online erschienen am 31.05.2024. Verfasst von Ke Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human and Social Sciences, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France. Hauptthemen laut MEDLINE: COVID-19, Breast Neoplasms, Time-to-Treatment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Longer times between diagnosis and treatments of cancer patients have been estimated as effects of the COVID-19 pandemic. However, relatively few studies attempted to estimate actual delay to treatment at the patient level.
Objective
To assess changes in delays to first treatment and surgery among newly diagnosed patients with localized breast cancer (BC) during the COVID-19 pandemic.
Methods
We used data from the PAPESCO-19 multicenter cohort study, which included patients from 4 French comprehensive cancer centers. We measured the delay to first treatment as the number of days between diagnosis and the first treatment regardless of whether this was neoadjuvant chemotherapy or surgery. COVID-19 pandemic exposure was estimated with a composite index that considered both the severity of the pandemic and the level of lockdown restrictions. We ran generalized linear models with a log link function and a gamma distribution to model the association between delay and the pandemic.
Results
Of the 187 patients included in the analysis, the median delay to first treatment was 42 (IQR:32–54) days for patients diagnosed before and after the start of the 1 st lockdown (N = 99 and 88, respectively). After adjusting for age and centers of inclusion, a higher composite pandemic index (> = 50 V.S.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Human and Social Sciences, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
- Department of Biostatistics, Institut de Cancérologie de l'Ouest, St-Herblain, France.
- Department of Health Promotion and Prevention, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
ORCID-Profile: Ke Zhou, Jean-Sébastien Frenel, Martine M Bellanger
Zitieren
APA
Zhou, K., Robert, M., Seegers, V., Blanc-Lapierre, A., Savouroux, S., Bigot, F., Frenel, J. S., Campone, M., Conroy, T., Penault-Llorca, F., Raoul, J. L., & Bellanger, M. M. (2024). Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study. PLOS ONE, 19(5), e0304556. https://doi.org/10.1371/journal.pone.0304556
Vancouver
Zhou K, Robert M, Seegers V, Blanc-Lapierre A, Savouroux S, Bigot F, et al. Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study. PLOS ONE. 2024;19(5):e0304556. doi:10.1371/journal.pone.0304556
BibTeX
@article{Zhou2024,
author = {Zhou, Ke and Robert, Marie and Seegers, Valérie and Blanc-Lapierre, Audrey and Savouroux, Stéphane and Bigot, Frédéric and Frenel, Jean-Sébastien and Campone, Mario and Conroy, Thierry and Penault-Llorca, Frédérique and Raoul, Jean-Luc and Bellanger, Martine M},
title = {Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0304556},
doi = {10.1371/journal.pone.0304556}
}
EUVIMED